MS and COVID-19 challenge: asymptomatic COVID-19 infection during treatment with cladribine
Neurological Sciences, cilt.42, sa.9, ss.3533-3535, 2021 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 42 Sayı: 9
- Basım Tarihi: 2021
- Doi Numarası: 10.1007/s10072-021-05409-6
- Dergi Adı: Neurological Sciences
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CINAHL, EMBASE, Index Islamicus, MEDLINE, Psycinfo
- Sayfa Sayıları: ss.3533-3535
- Anahtar Kelimeler: Multiple sclerosis, Cladribine, COVID-19, SARS-CoV-2 antibody response
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Background: The use of disease-modifying therapies (DMTs) in people with multiple sclerosis (pwMS) may affect COVID-19 infection outcomes due to DMTs’ immunomodulatory and immunosuppressive effects on immune response. The yet unknown issues are both the early response to the infection, as well as the post-infection development of immunity against the virus under these treatments due to their interaction with the immune system. Methods: We report two asymptomatic cases of COVID-19 in patients with relapsing–remitting multiple sclerosis (RRMS) shortly after starting cladribine therapy, both developed anti-SARS-CoV-2 antibody response. Results: Patients with MS who are under newly initiated treatment with cladribine tablets may experience an asymptomatic COVID-19 infection and they may develop immunity against SARS-CoV-2. Conclusion: These observations raise the probability that DMTs with immunosuppressive effects, such as cladribine, may be considered as a treatment option for selected MS patients with high disease activity during the COVID-19 pandemic.